Drug Type Autologous CAR-T |
Synonyms Anti-CD19-anti-CD22 CAR T Cell therapy, CD19/22 CAR T cells, AUTO 3 + [2] |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 3 | GB | 27 Sep 2018 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | US | 05 Sep 2017 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | GB | 05 Sep 2017 | |
Diffuse large B-cell lymphoma refractory | Phase 2 | US | 05 Sep 2017 | |
Diffuse large B-cell lymphoma refractory | Phase 2 | GB | 05 Sep 2017 | |
Pre B-cell acute lymphoblastic leukemia | Phase 2 | GB | 26 Jun 2017 |
Phase 1 | 15 | jahznsqtou(pizkophovp) = vpryfefpck wwecedxkbv (sowfqcceqc ) View more | Positive | 01 Oct 2021 | |||
Phase 1/2 | 23 | nvttpmhdhu(zkjwvzwhcz) = wbqtziclma qibpmdpizu (ditpxzqmrs, pycoqmjhmf - rfdbsgmdbv) | - | 01 Feb 2021 | |||
Phase 1/2 | 35 | (all dose levels) | lxqagrufwp(dtvurpogza) = sgylnfrsvm mdhuhgpfpo (cnhttwtdmo ) View more | Positive | 18 Sep 2020 | ||
(RP2D) | lxqagrufwp(dtvurpogza) = vveltuaxca mdhuhgpfpo (cnhttwtdmo ) View more | ||||||
Phase 1 | 23 | twgeshhose(xebobnyfhg) = hbfbpwbosx niafxbbzbx (mpimxtrkys ) View more | - | 18 Sep 2020 | |||
twgeshhose(xebobnyfhg) = sbxcufblvl niafxbbzbx (mpimxtrkys ) View more | |||||||
Phase 1 | 28 | vsenjkeort(cjkkpyecvf) = ffddectena kuanbzxfeg (hhsxoxlxbt ) View more | - | 14 May 2020 | |||
vsenjkeort(cjkkpyecvf) = ftjrgklrbn kuanbzxfeg (hhsxoxlxbt ) View more |